Organisation: Zonegran

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

business

Elan reports first profit in decade

IRISH pharmaceutical group Elan saw its net loss widen significantly — due to a one-off cost — last year, but also posted its first operating profit for almost a decade.

business

Violations to cost Elan €152m

business

Elan positive despite losses of $43m

business

Elan in line for record growth

business

Elan revenues down 23%

business

Iseq closes down 40

Elan's Zonegran deal goes through

Elan has completed the sale of its North American and European interests in Zonegran to Eisai Inc. for €109m.

Wed, 28 Apr, 2004

Elan aims to complete Zonegran deal in April

Pharmaceutical firm Elan has sold its interests in anti-epileptic drug Zonegran to Eisai for $130m (€106.41m) if the deal is finalised by the end of April.

Wed, 31 Mar, 2004

ISEQ closes on slim gain

In Dublin, the ISEQ index was up 4.91 points to 4628.20, or 11%, barely keeping itself out of negative territory.

Fri, 21 Nov, 2003

Elan complete royalty rights deal

Irish pharmaceutical firm Elan has completed the acquisition of the royalty rights of three drugs from Pharma Operating.

Fri, 21 Nov, 2003